📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-16 16:51
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
9 announcements match the current filters (relevance ≥ 5).
Vilin Bio Med Shareholders Approve Chemgenix Merger with 100% Votes in Favour
Vilin Bio Med Limited announced the results of its NCLT-convened meeting held on October 15, 2026, regarding the Scheme of Amalgamation with Chemgenix Laboratories Private Limited. The special resolution was approved unanimously with 100% of polled votes in favour, totaling 24,83,085 votes. Overall voter turnout stood at 16.28% of the company's total 1,52,50,000 equity shares, with promoter participation accounting for 22,45,660 polled votes. The amalgamation now awaits subsequent regulatory and final NCLT sanctions.
Confidence: HIGH
What changedEquity shareholders and creditors have formally approved the Scheme of Amalgamation with Chemgenix Laboratories Private Limited.
Why it mattersThe merger with Chemgenix Laboratories can broaden Vilin Bio Med's pharmaceutical footprint and manufacturing scale beyond its current Roorkee bulk drugs facility.
Total shares voted in favour: 2483085Total outstanding shares: 15250000Voting turnout: 16.28%Votes in favour ratio: 100.00%
📅 Short termClearance from shareholders clears a major procedural hurdle, directing investor attention to the final NCLT order and timetable.
📈 Long termIf successfully integrated, the amalgamation may bolster operational capacities and product portfolio for the micro-cap bulk drugs company.
⚠ Risk flags
- Final approval is still subject to NCLT sanction and compliance with statutory clearances
- Low total voting participation at 16.28% of total equity base
Key Highlights
100.00% of polled votes (24,83,085 votes) voted in favour of the Scheme of Amalgamation
Overall voter turnout was 16.28% across 1,52,50,000 total outstanding shares
Promoter group polled 22,45,660 votes (26.00% of promoter holding), all in favour
Public non-institutional shareholders cast 2,37,425 votes (3.61% turnout), all in favour
👀 What to Watch
Track the upcoming NCLT Hyderabad bench hearings for the final sanction of the merger scheme, along with any subsequent disclosures detailing Chemgenix's financials and share swap ratios.
Vilin Bio Med Concludes NCLT-Convened Meetings for Chemgenix Laboratories Merger
Vilin Bio Med conducted NCLT-convened meetings of its equity shareholders and unsecured creditors on October 15, 2026, pursuant to a September 10, 2026 NCLT order. The meetings were held to seek approval for the proposed Scheme of Amalgamation between Chemgenix Laboratories Private Limited (Transferor) and Vilin Bio Med Limited (Transferee). A total of 12 equity shareholders (5 in person, 7 via video conference) and 1 creditor attended. Official voting outcomes are pending the submission of the scrutinizer's report.
Confidence: HIGH
What changedVilin Bio Med completed the NCLT-directed shareholder and creditor meetings required to proceed with the Chemgenix Laboratories amalgamation.
Why it mattersMerger with Chemgenix Laboratories could alter Vilin Bio Med's operational scale and share capital base (current market cap: Rs 81 Cr, TTM revenue: Rs 57 Cr).
Shareholders Present (In Person): 5Shareholders Present (VC/OAVM): 7Creditors Present: 1Meeting Date: October 15, 2026
📅 Short termVoting results from the scrutinizer will be released within days; stock may trade sideways until final resolution approval is confirmed.
📈 Long termIf approved by NCLT, the amalgamation could expand production assets or product portfolios beyond the existing Roorkee facility, subject to dilution terms.
⚠ Risk flags
- Financial details and valuation terms of Chemgenix Laboratories are not disclosed in the filing
- Potential equity dilution risk depending on the merger swap ratio
- Merger remains subject to final NCLT approval
Key Highlights
Held NCLT-convened equity shareholder meeting at 11:00 AM on October 15, 2026, concluding at 11:11 AM
Separate unsecured creditors meeting convened on October 15, 2026, at 12:30 PM with 1 creditor in attendance
Scheme involves the amalgamation of Chemgenix Laboratories Private Limited into Vilin Bio Med Limited
Remote e-voting was open from October 12, 2026 (09:00 AM) to October 14, 2026 (05:00 PM)
👀 What to Watch
Track the filing of scrutinizer voting results and subsequent NCLT sanction hearings, along with the swap ratio and financial disclosures regarding Chemgenix Laboratories.
NCLT Directs Vilin Bio Med to Convene Shareholder Meeting on Oct 15 for Chemgenix Merger
Vilin Bio Med has announced that the NCLT Hyderabad Bench has directed the company to convene a meeting of equity shareholders on October 15, 2026, to consider and approve the Scheme of Amalgamation with Chemgenix Laboratories Private Limited. The remote e-voting window is scheduled from October 12 to October 14, 2026, with an e-voting cut-off date of October 08, 2026. Creditors of the company have also been notified to submit representations, if any, within 30 days of receiving notice. The merger represents a material corporate restructuring for the Rs 88 Cr market cap company, though financial terms such as share swap ratios were omitted in this filing extract.
Confidence: HIGH
What changedNCLT has formally mandated shareholder and creditor approval processes for the proposed merger between Chemgenix Laboratories and Vilin Bio Med.
Why it mattersAmalgamation with Chemgenix Laboratories could significantly alter the asset base, manufacturing capacity, and equity dilution profile for a micro-cap firm with Rs 57 Cr TTM revenue.
Shareholder meeting date: October 15, 2026Cut-off date for e-voting: October 08, 2026Creditor representation window: 30 (thirty) daysMarket capitalization (context): Rs 88 Cr
📅 Short termShareholder attention will center on the voting results following the October 15, 2026 meeting and any potential creditor objections.
📈 Long termIf approved by shareholders and finally sanctioned by the NCLT, the amalgamation will structurally change the operational scale and share capital base of Vilin Bio Med.
⚠ Risk flags
- Dilution risk depending on the swap ratio issued to Chemgenix shareholders
- Merger is subject to NCLT final sanction and creditor approvals
Key Highlights
NCLT Hyderabad Bench issued an order on September 10, 2026, directing shareholder and creditor meetings.
Shareholder meeting scheduled for October 15, 2026, at 11:00 AM IST via physical and VC modes.
Cut-off date for e-voting is set for October 08, 2026.
Remote e-voting period runs from October 12, 2026 (9:00 AM) to October 14, 2026 (5:00 PM).
Creditors given 30 days from notice receipt to submit representations to the NCLT.
👀 What to Watch
Track the outcome of the October 15 shareholder vote and monitor disclosure of the final swap ratio and valuation details for Chemgenix Laboratories.
Vilin Bio Med Files Regulatory Undertaking for Amalgamation with Chemgenix Laboratories
Vilin Bio Med Limited has submitted an undertaking under Regulation 37 of SEBI LODR regarding its proposed Scheme of Arrangement for the amalgamation of Chemgenix Laboratories Private Limited into the company. The filing confirms compliance with NCLT directions per its order dated September 10, 2026, and applicable provisions under Sections 230-232 of the Companies Act, 2013. The merger remains subject to necessary statutory approvals before becoming effective, and specific financial terms or share exchange ratios were not detailed in this submission.
Confidence: MEDIUM
What changedVilin Bio Med provided formal undertaking of statutory and NCLT order compliance for its proposed merger with Chemgenix Laboratories.
Why it mattersA successful amalgamation could expand manufacturing capabilities and asset base beyond its existing Rs 28 Cr net worth, but final financial terms remain undisclosed.
NCLT Order Date: September 10, 2026Companies Act Sections: 230 – 232Deal Financial Consideration: not disclosed
📅 Short termNeutral to procedural in the near term as the scheme progresses through regulatory and tribunal scrutiny.
📈 Long termCould alter operational scale and revenue capacity structurally, depending on Chemgenix Laboratories' asset size and integration synergies.
⚠ Risk flags
- Deal terms and dilution/swap ratio not disclosed in this update
- Pending final approvals from shareholders, creditors, and regulatory authorities
Key Highlights
Submitted undertaking under Regulation 37 of SEBI LODR for amalgamation with Chemgenix Laboratories Private Limited
Company confirmed compliance with NCLT Order dated September 10, 2026
Scheme involves merger under Sections 230 to 232 of the Companies Act, 2013
Merger remains pending necessary regulatory and authority approvals
👀 What to Watch
Track subsequent filings for the disclosure of swap ratios, valuation reports, and shareholder meeting schedules mandated by the NCLT.
Vilin Bio Med Files Regulatory Undertaking for Amalgamation with Chemgenix Laboratories
Vilin Bio Med Limited (market cap ₹88 Cr) has submitted an undertaking under Regulation 37 of SEBI LODR confirming that its proposed scheme of amalgamation with Chemgenix Laboratories Private Limited complies with applicable laws and accounting standards. This follows directions from an NCLT Order dated September 10, 2026 under Sections 230–232 of the Companies Act, 2013. The merger remains subject to final regulatory and statutory approvals before coming into effect. Specific swap ratios and financial terms for Chemgenix were not disclosed in this specific filing.
Confidence: MEDIUM
What changedVilin Bio Med submitted an undertaking affirming that its proposed amalgamation with Chemgenix Laboratories adheres to legal and regulatory frameworks per NCLT directions.
Why it mattersThe merger could alter Vilin Bio Med's operational scale and manufacturing profile, though detailed financial consolidation figures and dilution impact remain to be disclosed.
NCLT Order date: September 10, 2026SEBI LODR Regulation: Regulation 37Company Market Cap: ₹88 CrCompany TTM Revenue: ₹57 Cr
📅 Short termThis is a procedural compliance filing under Regulation 37; minimal immediate market reaction expected until share swap ratios and target financials are announced.
📈 Long termIf successfully merged, Chemgenix Laboratories could add scale or new manufacturing capabilities to Vilin Bio Med's base ₹57 Cr TTM revenue business.
⚠ Risk flags
- Potential equity dilution risk depending on share swap ratio
- Regulatory approval delays (NCLT, SEBI, stock exchanges)
Key Highlights
Scheme involves the amalgamation of Chemgenix Laboratories Private Limited into Vilin Bio Med Limited
Filing confirms compliance pursuant to NCLT Order dated September 10, 2026
Application submitted under Regulation 37 of SEBI LODR Regulations, 2015
Scheme will become effective after obtaining all necessary regulatory and shareholder approvals
👀 What to Watch
Track subsequent exchange filings for the disclosure of the share exchange ratio, valuation report, and the final NCLT hearing dates for the merger.
NCLT Orders Meetings for Vilin Bio Med's Merger with Chemgenix Laboratories
Vilin Bio Med Limited (market cap ₹89 Cr) has received an order dated September 10, 2026, from the NCLT Hyderabad Bench allowing its joint company scheme application for amalgamation with Chemgenix Laboratories Private Limited. The tribunal dispensed with the meeting of Chemgenix's equity shareholders following 100% consent, while directing Vilin Bio Med to convene separate meetings for its shareholders and creditors. Chemgenix specializes in oncology Active Pharmaceutical Ingredients (APIs) and specialty chemicals with a paid-up capital of ₹9.69 Cr, compared to Vilin Bio's ₹15.25 Cr paid-up capital. Notices must be issued at least 30 days prior to the scheduled meetings.
Confidence: HIGH
What changedNCLT Hyderabad has progressed the proposed merger by dispensing Chemgenix's shareholder meeting and ordering Vilin Bio Med to convene shareholder and creditor meetings.
Why it mattersThe merger brings oncology API and specialty chemical capabilities to Vilin Bio Med's existing formulation business, potentially improving operating margins above its current 7.0% TTM baseline.
Chemgenix Paid-up Capital: Rs 9.69 CrVilin Bio Med Paid-up Capital: Rs 15.25 CrChemgenix Paid-up vs Vilin Bio Med Paid-up: ~63.5%Advance notice required for meetings: at least 30 days
📅 Short termShareholders and creditors of Vilin Bio Med will vote on the proposed amalgamation once formal notices are issued.
📈 Long termIf approved and sanctioned by NCLT, the consolidation into oncology APIs offers structural integration and potential margin expansion for Vilin Bio Med.
⚠ Risk flags
- Share swap ratio and exact dilution details not fully detailed in this specific order extract
- Execution and regulatory risks pending final approvals from creditors, shareholders, and sectoral regulators
- Both entities share the same registered office address in Hyderabad, indicating potential related-party dynamics
Key Highlights
NCLT Hyderabad Bench allowed joint scheme application CA (CAA) No. 29/230/HDB/2026 via order dated September 10, 2026
Shareholder meeting dispensed for transferor Chemgenix Laboratories following full consent
Chemgenix Laboratories brings paid-up capital of Rs 9.69 Cr (96,90,000 equity shares of Rs 10 each)
Transferee Vilin Bio Med has paid-up share capital of Rs 15.25 Cr across 1,52,50,000 equity shares
Meetings of Vilin Bio Med's shareholders and creditors ordered with at least 30 days' advance notice
👀 What to Watch
Track the notices specifying the exact dates for the shareholder and creditor meetings, along with the share exchange ratio and financial disclosures of the unlisted transferor company.
Vilin Bio Med Receives NSE 'No Objection' for Merger with Chemgenix Laboratories
Vilin Bio Med Limited has received an observation letter with 'No Objection' from the National Stock Exchange (NSE) dated August 10, 2026, regarding its proposed merger with Chemgenix Laboratories Private Limited. This follows the initial merger announcement made on February 16, 2026. The scheme now moves toward the next stages of approval, including shareholders, creditors, and statutory authorities (NCLT). Given Vilin Bio's small market cap of ₹66 Cr and TTM revenue of ₹57 Cr, this amalgamation could be a significant event for the company's scale.
Confidence: HIGH
What changedThe proposed merger has cleared the stock exchange regulatory hurdle, allowing the company to proceed with NCLT and shareholder approvals.
Why it mattersFor a small-cap pharma company with thin 7% operating margins, this merger represents a strategic attempt to scale operations or integrate manufacturing capabilities, which is critical for long-term sustainability.
NSE Approval Date: August 10, 2026Initial Intimation Date: February 16, 2026TTM Revenue: ₹57 CrMarket Cap: ₹66 Cr
📅 Short termThe stock may see positive sentiment due to the regulatory progress, though the final impact depends on the valuation of the merging entity.
📈 Long termIf successfully integrated, the merger could expand the company's manufacturing footprint beyond its current Roorkee unit and improve its competitive position in the unbranded pharma space.
⚠ Risk flags
- Equity dilution risk depending on the swap ratio
- Regulatory approval risk from NCLT
- Integration risk of the transferor company
Key Highlights
Received NSE 'No Objection' observation letter on August 10, 2026.
Amalgamation involves Chemgenix Laboratories Private Limited (Transferor) into Vilin Bio Med Limited (Transferee).
The merger process was initiated approximately 6 months ago on February 16, 2026.
Company currently operates with a lean TTM revenue of ₹57 Cr and a market cap of ₹66 Cr.
👀 What to Watch
Investors should monitor the upcoming disclosures regarding the swap ratio and the financial health of Chemgenix Laboratories to evaluate potential equity dilution versus earnings accretion.
Vilin Bio Med Registers as Manufacturer Exporter with Pharmexcil for Global Expansion
Vilin Bio Med (Market Cap: ₹60 Cr) has officially registered as a 'Manufacturer Exporter' with the Pharmaceuticals Export Promotion Council of India (Pharmexcil). This registration is a critical regulatory step enabling the company to export its pharmaceutical products and access international B2B markets. Given the company's current TTM revenue of ₹57 Cr and thin net margins, this move is intended to leverage its Roorkee manufacturing unit for higher-value international trade. While no specific orders were announced, this provides the legal and institutional framework for global market entry.
Confidence: HIGH
What changedVilin Bio Med has transitioned from a domestic-focused manufacturer to a registered exporter with Pharmexcil.
Why it mattersThis is a prerequisite for international expansion; it allows the company to diversify its revenue streams beyond the domestic unbranded market where it currently faces thin margins and high raw material sensitivity.
TTM Revenue: ₹57 CrMarket Cap: ₹60 CrOperating Profit Margin: 7.0%Debt-to-Equity: 0.01
📅 Short termThe announcement is sentimentally positive as it signals growth intent, though immediate financial impact is unlikely until export orders are secured.
📈 Long termIf executed well, this could lead to a structural shift in the business model from a domestic price-taker to an international supplier, potentially improving margins and scale.
⚠ Risk flags
- Execution risk in entering competitive international markets
- High raw material cost sensitivity (exceeding 90% of revenue)
- Regulatory compliance risks in foreign jurisdictions
Key Highlights
Registered as 'Manufacturer Exporter' with Pharmexcil as of August 1, 2026
Aims to leverage the existing Roorkee manufacturing unit for international market expansion
Targeting growth beyond the current TTM revenue of ₹57 Cr
Strategic move to improve global visibility and brand recognition for its unbranded portfolio
Registration facilitates access to export incentives and overseas B2B healthcare stakeholders
👀 What to Watch
Watch for the company's next quarterly results to see if export-related revenue begins to contribute. Investors should also monitor for any announcements regarding international quality certifications (like WHO-GMP) which are typically required to utilize this export registration effectively.
Vilin Bio Med Signs MOU with Ideal Pharma BV for European Medicine Distribution
Vilin Bio Med Limited (Market Cap: ₹60 Cr) has signed a Memorandum of Understanding (MOU) with Ideal Pharma BV, Netherlands, to collaborate on the distribution of generic and branded medicines across Europe. The partnership intends to leverage Ideal Pharma's established European wholesale distribution infrastructure. This represents a significant geographic expansion attempt for a company with a TTM revenue of ₹57 Cr. However, the MOU is non-binding regarding specific volumes, and definitive agreements are yet to be executed to finalize responsibilities.
Confidence: HIGH
What changedVilin Bio Med is moving from a domestic-focused unbranded generic supplier to establishing a distribution foothold in the European market through a Dutch partner.
Why it mattersFor a micro-cap company with ₹57 Cr revenue, successful European distribution could significantly improve margins and scale, provided they can meet stringent international regulatory standards.
TTM Revenue: ₹57 CrMarket Cap: ₹60 CrNet Worth: ₹28 CrPromoter Holding: 56.6%Debt-to-Equity: 0.01
📅 Short termThe stock may see positive sentiment due to the international expansion narrative, but the immediate impact is limited until definitive orders are booked.
📈 Long termIf executed, this could pivot the company from a low-margin price-taker in India to a higher-value exporter, structurally improving its 10.8% ROCE.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Non-binding MOU status
- Execution risk in highly regulated European markets
- Small scale of operations relative to international logistics
Key Highlights
MOU signed on July 29, 2026, with Netherlands-based Ideal Pharma BV for European market entry.
Collaboration covers both Generic and Branded Medicines using existing wholesale infrastructure.
Vilin Bio Med currently operates with a thin 7.0% OPM and TTM revenue of ₹57 Cr.
The agreement involves no equity issuance, special management rights, or changes in capital structure.
Definitive agreements are required to govern specific future transactions or projects.
👀 What to Watch
Monitor for the transition from this MOU to 'Definitive Agreements' with specific order values. Investors should also track if the company's Roorkee manufacturing unit requires further international certifications (like EU-GMP) to fulfill this partnership.
